ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Boehringer and Inflammasome form eye disease pact

by Lisa M. Jarvis
September 27, 2019 | APPEARED IN VOLUME 97, ISSUE 38

 

Boehringer Ingelheim and Inflammasome Therapeutics will work together on therapies for serious eye diseases. Under the broad pact, worth up to $160 million for Inflammasome, a long-acting, degradable intravitreal implant from Inflammasome will be used to deliver up to three compounds from Boehringer’s retinal disease pipeline. That pipeline includes clinical-stage treatments for macular degeneration, diabetic retinal diseases, and other eye disorders.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment